WuXi Biologics debuts new commercial drug product plant
Anticipated capacity of GMP facility is 60 million vials per year
WuXi Biologics, a contract development and manufacturing organization (CDMO), has launched the good manufacturing practice (GMP) operation of its new drug product facility located in Wuxi, China. This marks the eighth operational drug product facility in the WuXi global network.
The 129,000-plus-square-foot plant, known as DP2, includes an isolator filling line for the production of a wide size range. According to the CDMO, the center is capable of quickly switching between different specifications to maximize its filling efficiency. DP2 is expected to increase up to 60 million vials for commercial drug production of biologics per year.
The facility is also able to reportedly eliminate cross-contamination and provide product sterility. Further, the use of both single-use and stainless-steel formulation systems can also help lower energy consumption.
“Our business strategy in both building and acquiring new facilities has been driven by global customer demand and the robust biologics market,” notes Chris Chen, PhD, CEO of WuXi Biologics.
Understanding the FDA's Exemption for DSCSA Compliance
November 12th 2024In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.
